P95 BV, a full-service Contact Research Organization (CRO) specializing in vaccine development and infectious diseases, and LatinaBA, a regional CRO with over 15 years conducting clinical trials in Latin America, are pleased to announce their strategic partnership, aimed at propelling vaccine and infectious disease research in Latin America.
This collaboration will leverage the strengths and resources of both organizations to enhance the execution of clinical and epidemiological trials across Latin America. By providing tailored services throughout all phases of clinical research, now with an extended reach to additional countries in the region, P95 and LatinaBA together stand at the forefront of conducting impactful clinical trials in Latin America.
Health Technology Insights: ESTEAM Health Presents Inaugural Leader in Wellness Award to Retreat Healthcare
Thomas Verstraeten, CEO of P95, comments, “We are thrilled to establish a partnership that extends our close collaboration with Mariano and his team. LatinaBA has a profound knowledge of Latin American research needs and capabilities. Combined with our expertise in vaccine and infectious disease development, we will jointly be able to better serve the needs of vaccine manufacturers and others in Latin America and beyond.”
Health Technology Insights: IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO)
Mariano Zarzecki, CEO of LatinaBA, adds, “We are pleased to strategically partner with P95 and start a collaboration to boost vaccine and infectious disease research in Latin America, combining the expertise of both companies. Working with Thomas and the P95 team will enhance our clients’ opportunities and bring more treatment options for our patients.“
Health Technology Insights: Change to the Roche Enlarged Corporate Executive Committee
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prnewswire
